Skip to main content

Table 1 Characteristics of included studies

From: Meta-analysis of the safety of voriconazole in definitive, empirical, and prophylactic therapies for invasive fungal infections

Year Author Multicenter Therapeutic purpose Antifungals Sample size Age Underlying Disease Dosing regimen Duration
2001 Ally Y D VRC 200 18–75 Esophageal Candidiasis, AIDS 200 mg, oral, bid 14d
FLU 191 18–76 Esophageal Candidiasis, AIDS 200 mg, oral, qd 15d
2002 Lazarus Y P VRC 18 23–61 HM & solid tumor 200/300 mg, oral, q12h 14d
FLU 6 23–62 HM & solid tumor 400 mg, oral, qd 14d
2002 Herbrecht Y D VRC 144 48.5 HM, SOT, AIDS 200 mg, oral/i.v., bid 77d
AMBD 133 50.5 HM, SOT, AIDS 1–1.5 mg/kg, i.v., qd 10d
2002 Walsh Y E VRC 415 46.3 FN, HM or other cancers 200 mg, oral, q12h 7d
LAMB 422 45 FN, HM or other cancers 3 mg/kg, i.v. qd 7d
2005 Kullberg Y D VRC 248 53.6 Candidaemia 200 mg, bid 15d
AMB/FLU 122 53.3 Candidaemia AMB 0.7–1.0 mg/kg, oral/i.v., qd, 15d
Flu, 400 mg, oral/i.v. qd
2007 Queiroz-Telles Y D VRC 35 48.3 Paracoccidioidomycosis 200 mg, oral, bid 169d
ITRA 18 48.7 Paracoccidioidomycosis 100 mg, oral, bid 200d
2010 Wingard Y P VRC 305 43 AHSCT 200 mg, oral, bid 100d
FLU 295 43 AHSCT 400 mg, oral, qd 100d
2010 Kohno. Y D VRC 54 69.9 Tuberculosis sequelae 4 mg/kg, i.v., bid 3w
MCF 53 72.1 Tuberculosis sequelae 150–300 mg, i.v., qd 3w
2010 Oyake 1 Y E VRC 46 NA FN patients with AML 4 mg/kg, i.v., bid 9d
MCF 49 NA FN patients with AML 150 mg, i.v., qd 10d
2011 Bansal N D VRC 15 36.3 CISA 200 mg (adults), 100 mg (children), oral, q12h; 12w
AMB 18 36.3 CISA 1 mg/kg, i.v., qd 14w
2011 Mattiuzzi N P VRC 71 36.3 AML + MDS 300 mg, i.v., bid 20d
ITRA 52 60 AML + MDS 200 mg, i.v., qd 21d
2012 Shang Y D VRC 34 37.5 Kidney transplant 4 mg/kg, i.v., q12h 2.9 m
MCF 31 39.2 Kidney transplant 100 mg (<60 kg), qd; 3.8 m
150 mg (>60 kg), i.v., qd
2013 Gao Y P VRC 224 42.3 AHSCT 200/100 mg, oral/i.v., bid 96d
ITRA 241 42.3 AHSCT 200 mg, oral/i.v., bid 68d
2014 Hayashi Y P VRC 33 NA AHSCT 200 mg, oral, bid NA
ITRA 33 NA AHSCT 2.5 mg/kg, oral/i.v., bid NA
2016 Maertens Y D VRC 258 51.2 HM 4 mg/kg/200 mg, oral/i.v., bid 47d
ISA 258 51.1 HM 200 mg, oral/i.v., qd 45d
2016 Oyake 2 Y E VRC 50 53 FN with hematopathy 4 mg/kg, i.v., bid 9d
MCF 50 53 FN with hematopathy 150 mg, i.v., qd 12d
  1. Y Yes, N No, NA not available, D definitive treatment, E empirical treatment, P prophylaxis, VRC voriconazole, FLU fluconazole, AMBD amphotericin B deoxycholate, LAMB liposome amphotericin B, AMB amphotericin B, ITRA itraconazole, MCF micafungin, ISA isavuconazole, HM hematological malignancy, SOT solid organ transplantation, FN febrile neutropenia, AHSCT allogeneic hematopoietic stem cell transplantation, AML acute myeloid leukemia, CISA chronic invasive sinus aspergillosis, MDS myelodysplastic syndrome
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us